Shuttle Pharma Provides Third Quarter 2024 Corporate Update

by B2i | Nov 13, 2024 | Press Releases

GAITHERSBURG, Md., Nov. 13, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

by B2i | Oct 29, 2024 | Press Releases

GAITHERSBURG, Md., Oct. 29, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Pays Off Senior Secured Convertible Note

by B2i | Oct 29, 2024 | Press Releases

GAITHERSBURG, Md., Oct. 29, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

by B2i | Oct 28, 2024 | Press Releases

GAITHERSBURG, Md., Oct. 28, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”),...

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

by B2i | Sep 16, 2024 | Press Releases

GAITHERSBURG, Md., Sept. 16, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...